8-K: Exicure Secures $10 Million Equity Financing, Reports Q3 2024 Results

Exicure, Inc. has entered into agreements for a $10 million equity financing and reported its third quarter 2024 financial results, highlighting a need for additional funding.

Summary

• Exicure, Inc. has secured a total of $10 million in equity financing through two agreements with HiTron Systems Inc.
• The first agreement, dated November 6, 2024, involves the sale of 433,333 shares at $3.00 per share, totaling $1.3 million, expected to close within ten days.
• A subsequent agreement on November 13, 2024, includes the sale of 2,900,000 additional shares at $3.00 per share, totaling $8.7 million, contingent on stockholder approval.
• HiTron will gain board nomination rights proportional to its equity stake, subject to board approval.
• The company's cash and cash equivalents were $0.3 million as of September 30, 2024, down from $0.8 million at the end of 2023.
• Exicure reported a net loss of $1.1 million for the third quarter of 2024, compared to a $5.3 million loss in the same period of 2023.
• General and administrative expenses decreased to $1.46 million in Q3 2024 from $2.4 million in Q3 2023.
• The company recorded a $1.1 million increase in litigation legal expenses due to accruals related to a securities litigation lawsuit.
• Exicure received $1.5 million in gross proceeds from the sale of certain assets, including its historical biotechnology intellectual property.
• Management has stated that the company's current cash is insufficient to fund operations and that substantial additional financing is needed.

Sentiment

Score: 3

Explanation: The document highlights a critical need for additional funding and the risk of delisting, overshadowing the positive aspects of the equity financing and reduced losses. The overall sentiment is negative due to the company's precarious financial situation.

Positives

• The $10 million equity financing provides a much-needed capital injection for the company.
• The net loss decreased by $4.2 million year-over-year, indicating some improvement in financial performance.
• The sale of assets generated $1.5 million in revenue.
• General and administrative expenses have decreased due to reduced operations and separation costs.

Negatives

• The company's cash position is critically low at $0.3 million, insufficient to fund operations.
• The company has a net loss of $1.1 million for the quarter ended September 30, 2024.
• The company has a significant increase in litigation legal expenses of $1.1 million.
• The company is dependent on additional financing to continue operations.

Risks

• The company's cash reserves are insufficient to continue operations, requiring substantial additional financing.
• There is no guarantee that the company will secure additional financing or that it will be on acceptable terms.
• The company is at risk of being delisted from the Nasdaq Capital Market if it cannot demonstrate compliance with listing requirements.
• The company is facing ongoing litigation, which is incurring significant legal expenses.

Future Outlook

The company is exploring strategic alternatives to maximize stockholder value and needs to raise substantial additional financing in the very near term to continue operations.

Management Comments

• Management believes that the company's existing cash and cash equivalents are not sufficient to continue to fund operations.
• Management has stated that substantial additional financing is needed in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified.

Industry Context

The company's shift from an early-stage biotechnology company to exploring strategic alternatives reflects a broader trend in the biotech industry where companies with limited cash runways often seek mergers, acquisitions, or asset sales to maximize value.

Comparison to Industry Standards

• The company's cash position of $0.3 million is significantly below the industry average for publicly traded biotech companies, which typically maintain several million dollars in cash reserves to fund ongoing research and development.
• The net loss of $1.1 million for the quarter is not unusual for early-stage biotech companies, but the company's lack of revenue generation from operations is a concern.
• The company's reliance on asset sales for revenue is not a sustainable long-term strategy, and the company needs to secure additional funding to continue operations.
• The company's need for additional financing is a common challenge for biotech companies, but the company's current financial situation is more precarious than many of its peers.

Management Changes

Legal Proceedings

• The company has recorded accruals for the amount of the unsatisfied self insured retainer and legal defense costs related to the securities litigation lawsuit.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment if the company cannot secure additional financing and comply with Nasdaq requirements.
• Employees face uncertainty about the company's future and potential job security due to the company's financial difficulties.
• Creditors face the risk of non-payment if the company cannot secure additional financing.

Next Steps

• The company needs to close the initial $1.3 million equity investment.
• The company needs to obtain stockholder approval for the subsequent $8.7 million equity investment.
• The company needs to secure additional financing to continue operations.
• The company needs to demonstrate compliance with Nasdaq listing requirements to avoid delisting.

Key Dates

Keywords

equity financing, biotechnology, strategic alternatives, cash position, net loss, Nasdaq, HiTron Systems Inc., board of directors, stockholder approval, delisting